Carbon Monoxide
In clinical developmentAlso known as CO, Carboneum oxygenisatum, carbon(II) oxide.
Recent clinical, regulatory, research and industry developments relating to this drug.
Effects of Carbon Monoxide Breathing on Blood Vessel Function
Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension
Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable COPD
Gases as biological messengers: nitric oxide and carbon monoxide in the brain.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes1
Journals, researchers & institutions
- Scientific reports1
- The Journal of neuroscience : the official journal of the Society for Neuroscience1
- Bečvář R1
- Bubová K1
- Dawson TM1
- Distler JHW1
- Heřmánková B1
- Komarc M1
- Oreská S1
- Pavelka K1
- Charles University1
- Department of Internal Medicine III and Institute for Clinical Immunology1
- Institute of Rheumatology1
- Johns Hopkins University School of Medicine1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 3 of the same disease areas as Carbon Monoxide in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials